Health & Fitness

Item Description

NAC Eye Drops contain the antioxidant N-Acetyl Carnosine 1.0% liquid.  Each box of NAC contains two vials, five milliliters each.  N-acetyl-carnosine eye drops is recommended for you and your pets. 

√ Reduces Cataracts 

√ Improves Eyesight

√ Improves Glare Sensitivity

NAC Eye Drops provide those suffering from cataracts a breakthrough alternative to cataract surgery.  This cataract melting formula discovered by Dr. Babizhayev and his research team delivers powerful anti-oxidant benefits and has generated amazing curative results for people around the world. 

References, Research & Articles:

Efficacy of NAC in Treatement of Cataracts

Suggested Use: Use 1 drop in each eye twice daily

NAC eye drops contain 2 x 5ml bottles. Each bottle contains approx 80 drops. One box under normal daily usage should last 1 month for both eyes. 

What is NAC?

NAC eye drops provide those suffering from cataracts a breakthrough alternative to cataract surgery.  This cataract melting formula discovered by Dr. Babizhayev and his research team delivers powerful anti-oxidant benefits and has generated amazing curative results for people around the world. 

NAC is the name we commonly use to refer to N-Acetylcarnosine.  N-Acetylcarnosine is a naturally occurring compound chemically related to the dipeptide carnosine. Other than the fact that it carries an additional acetyl group, NAC molecular structure is identical to carnosine. Carnosine is found in the heart and skeletal muscles and is believed to have anti-oxidant properties. 

Oxidative stress is one of the implications for the chemical reactions that lead to destructive age related cross linking and aggregation of proteins.  Unlike most dipeptides, carnosine  is not derived from proteins, and is soluble in water but not in lipids (fats).  As a result of this characteristic, carnosine has difficulty penetrating through cell membranes made of lipids, however N-acetylcarnosine is relatively soluble in lipids and in water and can therefore pass through cell membranes.   Once inside the cellular level, NAC is broken down into carnosine and the benefits can be derived.

Since NAC eye drops have N-acetylcarnosine, they are highly resistant to break down and have slow release characteristics making them highly effective in treating cataracts.  These drops will deliver a powerful anti-oxidant boost  to your eyes, protecting you from the potential for cataracts and improving existing cataract condition.

Background and Research:

The breakthrough behind NAC took place in the 1990’s as a result of research done by Dr. Mark Babizhayev and his Russian research team.  During early experiments performed at the Moscow Helmholtz Research Institute for Eye Diseases, it was shown that NAC (1% concentration), was able to pass from the cornea to the aqueous humour after about 15 to 30 minutes.

In another study NAC was reported as effective in improving vision in cataract patients and reduced the appearance of cataract. The authors called this ‘a snow melting effect’ referring to the slow reduction of the cataractous tissues in the lens following the use of NAC eye drops. Transparency of the lens improved after using NAC eye drops at a concentration of 1% twice a day for four months. These results were relevant to all forms of cataract, mild or severe, although other studies found the most beneficial effect was in relation to early forms of cataract. This was a landmark study, which caused many commercial operators to manufacture their own brands of anti-cataract NAC eye drops.

In a 2004 trial of 90 canine eyes with cataracts, led by Dr. Babizhayev, NAC was reported to have performed better than placebo in positively affecting lens clarity.   The Babizhayev group later published a placebo-controlled clinical trial of NAC in 76 human eyes with mild to advanced cataracts and reported similar positive results for NAC.

In a long-term study, researchers observed the changes in lens clarity over a 6 to 24 month period for 49 volunteers. The average age of the participants was 65, and all suffered from senile cataracts ranging from minimal to advanced opacification (clouding of the lens).  The patients received either a 1% solution of NAC eye drops or a placebo, as two drops twice a day in each eye. The patients were then evaluated after two months and again after six months.  The evaluations consisted of ophthalmoscopy (glare test), stereocinematagraphic (slit-image) and retro-illumination (photography). A computerized digital analysis then displayed the light scattering and absorbing effects of the centers of each lens.

Here is the outcome after six months:

• 88.9% of the patients who were treated with NAC had an improvement of glare sensitivity (lowest individual score was a 27% improvement, all the way up to a 100% improvement)
• 41.5% had a significant improvement of the transmissivity of the lens
• 90% showed an improvement in visual acuity

The patients in the placebo group exhibited little change in eye quality at 6 months and a gradual deterioration at 12 to 24 months.

Continued improvement

This study also showed that at 24 months the NAC treated group (who already had significant improvement to the quality of their eyesight), sustained these results with continued use of the NAC eye drops. There were no significant side effects noted in any cases throughout the two-year period.

Another Russian study evaluated two groups of 49 patients (with the average age being 65), who had advanced symptoms of cataracts. After a 24 month course of treatment, the group that was treated with the eye drops had a cumulative positive change when compared with the group that did not receive the eye drops.

References:

• Babizhayev, MA, Micans, P, Guiotto, A, Kasus-Jacobi, A, N-Acetylcarnosine Lubricant Eyedrops Possess All-In-One Universal Antioxidant Protective Effects of L-Carnosine in Aqueous and Lipid Membrane Environments, Aldehyde Scavenging, and Transglycation Activities Inherent to Cataracts: A Clinical Study of the New Vision-Saving Drug N-Acetylcarnosine Eyedrop Therapy in a Database Population of Over 50,500 Patients American Journal of Therapeutics: 30 May 2009 [Epub ahead of print.].

• Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, Zhukotskii AV, Goldman IM. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D 2002;3(2):87-103.

• Babizhayev MA, Yermakova VN, Semiletov YA, Deyev AI. The natural histidine-containing dipeptide N-alpha-acetylcarnosine as an antioxidant for ophthalmic use. Biochemistry (Mosc) 2000 May;65(5):588-98.